Comparison of antimicrobial resistance in Pseudomonas aeruginosa from intensive care and non-intensive care units and its impact on treatment decisions

This study compares antimicrobial resistance of P. aeruginosa from ICU and non-ICU patients, revealing that 30% were from ICU patients and 70% from non-ICU patients. Resistance to ciprofloxacin and piperacillin-tazobactam was higher in ICU patients than non-ICU patients. The prevalence of DTR P. aeruginosa was similar between the two groups, but joint resistance to imipenem and ceftazidime was more prevalent in ICU patients. Carbapenemase-producing strains were more frequent in ICU patients. Ceftolozane-tazobactam, which remains effective against DTR P. aeruginosa, could improve its adequacy by 21% in ICU and 19% in non-ICU patients compared to current first-line treatments.